Zeracizumab Is an Experimental Angiogenesis Inhibitor Targeting Vascular Endothelial Growth

Zeracizumab is an experimental angiogenesis inhibitor targeting vascular endothelial growth factor that is being tested for the treatment of advanced, chemotherapy-naive, non-squamous non-small cell lung cancer (NSCLC) .  Part of the drug company's evaluation process is to analyze the 1-year survival after treatment to determine the clinical efficacy of the experimental treatment.  The results are given in the table below. Which of the following best represents the number needed to harm for the zeracizumab-containing regimen?

A) 2
B) 25
C) 40
D) 72
E) 94

Correct Answer:

Verified

Unlock this answer now
Get Access to more Verified Answers free of charge

Access For Free